A5051983260- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Chronic Myeloid Leukemia Treatments
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- Renal Transplantation Outcomes and Treatments
- Antifungal resistance and susceptibility
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mesenchymal stem cell research
- Eosinophilic Disorders and Syndromes
- Pneumocystis jirovecii pneumonia detection and treatment
- Multiple Myeloma Research and Treatments
- Oral health in cancer treatment
- Childhood Cancer Survivors' Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Fungal Infections and Studies
- Mycobacterium research and diagnosis
- Transplantation: Methods and Outcomes
Tokyo Medical and Dental University
2021-2024
The University of Tokyo
2024
Keio University
2015-2024
Kyoto University
2015-2024
National Cancer Research Institute
2024
Institute of Science Tokyo
2024
Tokyo Medical University
2021
Keio University Hospital
2003-2021
The Japanese Data Center for Hematopoietic Cell Transplantation
2015
Novartis (Japan)
2007-2009
Cytomegalovirus (CMV) infection is a major infectious complication after allogeneic hematopoietic cell transplantation (allo-HSCT). Recently, it was reported that CMV reactivation associated with decreased risk of relapse in patients acute myeloid leukemia (AML). The aim this study to evaluate the impact early on incidence disease allo-HSCT large cohort patients. Japan Society for Hematopoietic Cell Transplantation's Transplantation-Related Complication Working Group retrospectively surveyed...
Knowing the impact of chronic graft-versus-host disease (GVHD) on quality life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study examine relationship between patient-reported QoL as measured Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment Cancer Therapy-Bone Marrow Transplant, visual analogue scale (VAS)...
We prospectively evaluated the incidence of human herpesvirus 6 (HHV-6) DNAemia after allogeneic hematopoietic stem cell transplantation (HSCT) using quantitative plasma real-time polymerase chain reaction. Of 46 recipients bone marrow or peripheral blood (BMT/PBSCT) from related (n = 11) unrelated donors 22), and cord (CBT) 13), 22 (47.8%) developed HHV-6 DNAemia. DNA levels ranged 200 to 200,000 copies/mL plasma, was observed significantly more frequently CBT than BMT/PBSCT (92.3% vs...
Systemic corticosteroid therapy is recommended as a first-line treatment for acute graft-versus-host disease (GVHD). We performed retrospective study to identify the factors affecting response of grade II IV GVHD systemic using Japanese national registry data patients who received first allogeneic hematopoietic cell transplantation with bone marrow (BM) (n = 1955), peripheral blood stem cells (PBSCs) 642), or umbilical cord (UCB) 839). Of 3436 patients, 2190 (63.7%) showed improvement...
We sought to assess the late mortality risks and causes of death among long-term survivors allogeneic hematopoietic stem cell transplantation (HCT). The cases 11,047 relapse-free a first HCT at least 2 years after were analyzed. Standardized ratios (SMR) calculated specific compared with those Japanese population. Among years, overall survival percentages 10 15 87% 83%, respectively. risk was significantly higher that general from infection (SMR = 57.0), new hematologic malignancies 2.2),...
Cord blood transplantation (CBT) is a distinct risk factor for human herpesvirus-6 (HHV-6) reactivation and HHV-6 encephalitis. In prospective multicenter trial we investigated the effects of prophylactic foscarnet (90 mg/kg i.v. infusion from days 7 to 27 after CBT) on occurrence reactivation, encephalitis, acute graft-versus-host disease (aGVHD) in CBT recipients. Between 2014 2016, 57 patients were included foscarnet-prophylaxis group. Outcomes compared with an historical control group...
Dry eye disease (DED) is often elicited by graft-versus-host (GVHD), an extensive complication of hematopoietic stem cell transplantation (HSCT). To unravel the mechanism this type DED, in vivo confocal microscopy (IVCM) was used to investigate alterations state sub-basal nerves, dendritic cells (DCs) and globular immune (GICs) central cornea limbal epithelia. In study, we examined 12 HSCT recipients with GVHD-caused DED 10 without GVHD-associated evaluated clinical parameters 2 groups....
We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 autologous HSCT and 129 syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability developing PTLD at 2 years post-HSCT was .79% transplantation, .78% .11% transplantation. following variables were identified as risk factors...
To examine immune processes in the lacrimal gland of patients with chronic graft-versus-host disease (cGVHD) by evaluating expression surface molecules associated T-cell activation.Antibodies to CD4, CD8, CD34, CD40, CD54, CD80, CD86, CD154, and HLA-DR were used for immunohistochemical analysis biopsy specimens obtained from nine cGVHD five Sjögren's syndrome (SS). The regions interest further assessed transmission electron microscopy.CD4(+) CD8(+) T cells mainly detected periductal areas...
Recent advances in unrelated cord blood transplantation (UCBT) and high-resolution typing of human leukocyte antigen (HLA) from an donor have increased choices alternative donor/stem cell source selection. We assessed HLA-mismatched locus-specific comparison the outcomes 351 single-unit UCB 1,028 bone marrow (UBM) adult recipients 16 years old or older at time who received first stem with myeloablative conditioning for acute leukemia myelodysplastic syndromes. With adjusted analyses, HLA 0...